USPTO allows patent to biomedical company Nurexone
by CM staff
The patent covers Nurexone’s ExoPTEN drug compositions and treatment methods for Central Nervous System disease.
HAIFA and CALGARY — NurExone Biologic Inc., a biopharmaceutical company developing biologically-guided exosome therapy (ExoTherapy) for patients with traumatic spinal cord injuries, has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application NO. 17/042,441. The patent covers and protects NurExone Exo-PTEN technology, and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.
The patent discloses and claims inventions and methods in exosome technology, such as the pharmaceutical compositions comprising extracellular vesicles including exosomes, loaded with an exogenous inhibitor of phosphatase and tensin homolog (PTEN) inhibitor as well as a method for treating neuronal injury or damage, including intranasal administration.
The company intends to file additional patent applications with the USPTO as well as additional international patent applications (PCT) in order to further strengthen NurExone’s intellectual property portfolio. The patent was submitted by the Technion-Israel Institute of Technology and Ramot, a Tel Aviv University’s technology transfer company and is part of NurExone’s licensed intellectual property portfolio.
“We are delighted that the USPTO has determined that the patent application covering our proprietary drugs and methods of administration satisfies the requirements for patentability,” said Dr. Lior Shaltiel, CEO of NurExone. “The Patent will enable us to strengthen the IP barrier protecting our core technology, including the source of the cells, loaded siRNA and method of administration. This may enhance our ability to potentially commercialize and license technology to pharmaceutical companies. Moving forward, we plan to continue pursuing our intellectual property expansion strategy extending our competitive edge.”
NurExone Biologic Inc. is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.
